TransMedics Group, Inc. (TMDX)

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

• 年度报告（10-K）

  对公司业务、财务业绩和风险的年度概述。

  提交日期：2026-02-24

  查看文件

• 季度报告（10-Q）

  最近三个月财务表现的最新情况。

  提交日期：2026-08-04

  查看文件

• 临时报告（8-K）

  关于重大事件（如管理层变动或重要公告）的通知。

  提交日期：2026-09-10

  查看文件

• 3/8/2026POSITIVE
  TransMedics Stock Is Up 104% Over the Last Year: Is It Too Late to Buy for 2026?

  TransMedics Group Inc. has demonstrated remarkable growth, with its stock price surging 104% over the past year. The company is recognized for its innovative approach to revolutionizing the organ transplant industry. Despite this impressive performance, market sentiment remains divided, with some analysts labeling the stock as 'overvalued.' Investors are now contemplating whether the significant gains made thus far leave room for further appreciation by 2026, balancing the company's disruptive potential against current valuation concerns.

• 2/28/2026POSITIVE
  Got $5,000? TransMedics Could Be a High‑Tech Organ Transplant Moonshot

  TransMedics Group, Inc., a mid-cap healthcare specialist, is drawing investor attention as a potential 'moonshot' in the high-tech organ transplant sector. The company, focused on advanced solutions for organ preservation and transport, is seen as a significant investment opportunity for those seeking growth in innovative medical fields. Analysts suggest that with an initial capital of around $5,000, investors might consider a deeper look into this company, given its prominent position in a market segment with high expansion potential and technological innovation. Its technology could revolutionize current practices, offering attractive long-term return prospects.